Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time-Reference-Cited by-同舟云学术

Assessing the benefit of cancer drugs approved by the European Medicines Agency using the European Society for Medical Oncology Magnitude of Clinical Benefit Scale over time

Published:2021-06 Issue: Volume:150 Page:203-210
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Thomson Sasha,Witzke Noah,Gyawali Bishal,Delos Santos Seanthel,Udayakumar Suji^ORCID,Cardone Claudia,Cheung Matthew C.,Chan Kelvin K.W.^ORCID

Funder

Canadian Centre for Applied Research in Cancer Control

Canadian Cancer Society

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference33 articles.

1. American society of clinical oncology statement: toward individualized care for patients with advanced cancer;Peppercorn;J Clin Oncol,2011

2. Outcomes and endpoints in cancer trials: bridging the divide;Wilson;Lancet Oncol,2015

3. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13;Davis;BMJ,2017

4. Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of us food and drug administration approvals;Kim;JAMA Intern Med,2015

5. Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval?;Grössmann;ESMO Open,2016

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of changes in the clinical benefits of oncology drugs over time following reimbursement using the ASCO-VF and the ESMO-MCBS;Journal of Cancer Research and Clinical Oncology;2024-03-04

2. ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0;Annals of Oncology;2023-09

3. Cancer Drugs Reimbursed with Limited Evidence on Overall Survival and Quality of Life: Do Follow-Up Studies Confirm Patient Benefits?;Clinical Drug Investigation;2023-07-28

4. Clinical Benefit Scales and Trial Design: Some Statistical Issues;JNCI: Journal of the National Cancer Institute;2022-05-18

5. Applicability of ESMO-MCBS and ESCAT for molecular tumor boards;memo - Magazine of European Medical Oncology;2022-04-13